Foundation series

Quanterix receives funding from the Alzheimer’s Drug Discovery Foundation to accelerate the development of plasma tests for the diagnosis of Alzheimer’s disease

The funding will fuel a series of prospective clinical trials to validate Quanterix’s multi-analyte test in collaboration with Amsterdam University Medical Centers (Amsterdam UMC)

BILLERICA, Mass., March 29, 2022–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ: QTRX), a company that digitizes biomarker analysis to advance the science of precision health, today announced its partnership with Alzheimer’s Drug Discovery Foundation (ADDF) to accelerate the development of a multi-analyte plasma test for the early detection of Alzheimer’s disease. As part of this partnership, the ADDF will fund a series of prospective clinical trials to validate the test in collaboration with Amsterdam University Medical Centers (Amsterdam UMC). Charlotte Teunissen, Professor and Principal Clinical Investigator, will lead the clinical trials at UMC Amsterdam. The financial terms of this agreement were not disclosed. The work will be coordinated by the company’s Simoa® Acceleration Services Laboratory, a flagship laboratory providing contract research services and clinical sample testing, powering research for more than 400 companies and accelerating turnaround times. drug approval through the detection of biomarkers at the lowest possible levels.

“ADDF is a well-established philanthropic organization with a strong leadership position in the field and we look forward to partnering with them in our quest to validate a Simoa plasma test for Alzheimer’s disease,” said Kevin Hrusovsky, Chairman and CEO, Quanterix and Founder of Powering Precision Health (PPH). “We are delighted to receive funding from the ADDF aimed at accelerating the development of a multi-analyte test, as Alzheimer’s disease continues to be one of the greatest threats to global public health, with a enormous economic cost. It is now more important than ever to develop accessible diagnostic tests to help connect Alzheimer’s patients with emerging therapies early in the disease.”

“We are at a historic moment with plasma-based biomarkers for the detection of Alzheimer’s disease approaching clinical implementation. This partnership and funding with the ADDF will help accelerate rapid progress in this area just in time for the arrival of new therapies. We will be looking to validate the Simoa multi-analyte test for use in both memory care and primary care, in people with concerns about their cognition,” said Charlotte Teunissen, Professor and Principal Investigator at UMC Amsterdam.

ADDF’s mission is to rapidly accelerate the discovery of drugs to prevent, treat and cure Alzheimer’s disease. Founded in 1998 by Leonard A. and Ronald S. Lauder, the ADDF is the only public charity focused exclusively on funding drug development for Alzheimer’s disease. Through donor support, the ADDF has awarded more than $209 million to fund more than 690 Alzheimer’s disease drug discovery programs, biomarker programs and clinical trials in 19 countries.

“We have long believed that the path to approved treatments for Alzheimer’s disease begins with a better way to diagnose patients and monitor their response to treatment. Thanks to the diagnostic accelerator, the ADDF is accelerating the development of new biomarkers for the early detection of Alzheimer’s disease and related dementias. , which are critical to advancing research, allowing us to recruit the right patients into clinical trials and track their progress,” said Howard Fillit, co-founder and chief scientific officer of ADDF. “Advanced diagnostic tools like the multi-analyte blood test developed by Quanterix also have the potential to significantly improve accuracy and facilitate early diagnosis in clinical practice.”

To learn more about Quanterix’s Simoa® technology, visit:

About Diagnostic Accelerator

The Diagnostics Accelerator, established in July 2018, is a donor partnership with funding commitments totaling nearly $50 million over three years from partners including ADDF co-founder Leonard A. Lauder , Bill Gates, Jeff Bezos, MacKenzie Scott, the Dolby family, the Charles and Helen Schwab Foundation, The Association for Frontotemporal Degeneration, among others, to develop new biomarkers for the early detection of Alzheimer’s disease and related dementias.

This research initiative aims to accelerate the development of affordable and accessible biomarkers to diagnose Alzheimer’s disease and related dementias and advance the clinical development of more targeted treatments. Through translational research grants and access to advisory support from industry experts, this program will challenge, assist and fund the research community in academia and industry to develop novel biomarkers. peripherals and digital.

About Quanterix

Quanterix is ​​a company digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way healthcare is delivered today by giving researchers the ability to look closely at the health-to-illness continuum. Quanterix’s technology is designed to enable much earlier disease detection, better prognoses, and improved treatment methods to improve people’s quality of life and longevity for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For more information, visit

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.” and similar expressions (as well as other words or expressions that refer to future events, conditions or circumstances) are intended to identify the forward-looking statements. The forward-looking statements contained in this press release are based on Quanterix’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that could cause a difference between Quanterix’s actual results and those expressed or implied by the forward-looking statements in this press release are discussed in Quanterix’s filings with the United States Securities and Exchange Commission, including the “Factors in Risk” contained herein. Except as required by law, Quanterix assumes no obligation gation to update the forward-looking statements contained herein to reflect any changes in expectations, even when new information becomes available.

See the source version on


Media Contact:
PAN Communications
Paige Romine, (321) 652-8370
[email protected]

Contact with Investor Relations:
Etienne Hrusovsky
(774) 278-0496
[email protected]